Simulations Plus (SLP) said Wednesday it has partnered with the Enabling Technologies Consortium to advance GastroPlus platform and in vitro-in vivo correlation methods for oral drug delivery.

The funded collaboration will expand the GastroPlus platform by supporting its advanced compartmental absorption and transit model for immediate release products, the company said.

The improvements are expected to support the researchers speed up drug development, lessen the need for animal studies, and simplify regulatory filings, it added.

During the project, Simulations Plus will share beta versions of the enhanced GastroPlus software with ETC members for testing, and the final version will then be offered to all users, according to the company.

Simulations Plus will maintain ownership of any intellectual property resulting from the project, the company added.

Simulations Plus shares were up nearly 4% in recent trading.

Price: 32.82, Change: +1.16, Percent Change: +3.65